You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTravoprost
Accession NumberDB00287  (APRD01271)
TypeSmall Molecule
GroupsApproved
DescriptionTravoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a synthetic prostaglandin F2alpha analogue. [Wikipedia]
Structure
Thumb
Synonyms
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1e,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Travatan
Travatan Z
Travoprost
Travoprostum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IzbaSolution / drops30 μg/mlOphthalmicAlcon Laboratories (Uk) Ltd2014-02-20Not applicableEu
IzbaSolution / drops30 μg/mlOphthalmicAlcon Laboratories (Uk) Ltd2014-02-20Not applicableEu
IzbaSolution0.003 %OphthalmicAlcon Canada IncNot applicableNot applicableCanada
Mylan-travoprost ZSolution0.004 %OphthalmicMylan Pharmaceuticals UlcNot applicableNot applicableCanada
PMS-travoprost ZSolution0.004 %OphthalmicPharmascience IncNot applicableNot applicableCanada
Sandoz TravoprostSolution0.004 %OphthalmicSandoz Canada Incorporated2014-08-15Not applicableCanada
Teva-travoprost Z Ophthalmic SolutionSolution0.004 %OphthalmicTeva Canada Limited2014-08-18Not applicableCanada
TravatanSolution / drops40 μg/mlOphthalmicAlcon Laboratories (Uk) Ltd2001-11-27Not applicableEu
TravatanSolution / drops40 μg/mlOphthalmicAlcon Laboratories (Uk) Ltd2001-11-27Not applicableEu
TravatanSolution0.004 %OphthalmicAlcon Canada Inc2001-11-132010-11-16Canada
TravatanSolution / drops40 μg/mlOphthalmicAlcon Laboratories (Uk) Ltd2001-11-27Not applicableEu
TravatanSolution / drops40 μg/mlOphthalmicAlcon Laboratories (Uk) Ltd2001-11-27Not applicableEu
Travatan ZSolution / drops.04 mg/mLOphthalmicAlcon Laboratories, Inc2006-10-20Not applicableUs
Travatan ZSolution.04 mg/mLOphthalmicPhysicians Total Care, Inc.2008-12-09Not applicableUs
Travatan ZSolution0.004 %OphthalmicAlcon Canada Inc2008-11-10Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-travoprost ZSolution0.004 %OphthalmicApotex Inc2014-08-14Not applicableCanada
Travoprost Ophthalmic Solution 0.004%Solution.04 mg/mLOphthalmicPar Pharmaceutical, Inc.2013-04-152019-10-31Us
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Travo-ZNot Available
Brand mixtures
NameLabellerIngredients
Apo-travoprost-timopApotex Inc
Duotrav PqAlcon Canada Inc
Sandoz Travoprost / Timolol PqSandoz Canada Incorporated
SaltsNot Available
Categories
UNIIWJ68R08KX9
CAS number157283-68-6
WeightAverage: 500.5477
Monoisotopic: 500.238573467
Chemical FormulaC26H35F3O6
InChI KeyMKPLKVHSHYCHOC-AHTXBMBWSA-N
InChI
InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1
IUPAC Name
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]cyclopentyl]hept-5-enoate
SMILES
CC(C)OC(=O)CCC\C=C/C[[email protected]]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F
Pharmacology
IndicationOphthalmic solution used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.
Structured Indications
PharmacodynamicsTravoprost, an isopropyl ester prodrug, is a synthetic prostaglandin F2 alpha analogue that is rapidly hydrolyzed by esterases in the cornea to its biologically active free acid. The travoporst free acid is potent and highly selective for the FP prostanoid receptor.
Mechanism of actionTravoprost free acid is a selective FP prostanoid receptor agonist and is believed to reduce intraocular pressure by increasing the drainage of aqueous humor, which is done primarily through increased uveoscleral outflow and to a lesser extent, trabecular outflow facility.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin F2-alpha receptorProteinyes
agonist
HumanP43088 details
Related Articles
AbsorptionSystemically absorbed when administered to the eye.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Travoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to its biologically active free acid. Systemically, travoprost free acid is metabolized to inactive metabolites via beta-oxidation of the α(carboxylic acid) chain to give the 1,2-dinor and 1,2,3,4-tetranor analogs, via oxidation of the 15-hydroxyl moiety, as well as via reduction of the 13,14 double bond.

Route of eliminationLess than 2% of the topical ocular dose of travoprost was excreted in the urine within 4 hours as the travoprost free acid.
Half lifeTerminal elimination half-life of travoprost free acid is 45 minutes.
ClearanceNot Available
ToxicitySymptoms of overexposure include irritation to the skin, eyes, nose, throat, and respiratory tract.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Travoprost.Experimental
AcebutololTravoprost may increase the hypotensive activities of Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Aceclofenac.Approved
AcetovanilloneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Acetovanillone.Investigational
Acetylsalicylic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Adapalene.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Travoprost.Approved, Investigational
AliskirenTravoprost may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololTravoprost may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanTravoprost may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineTravoprost may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineTravoprost may increase the hypotensive activities of Amlodipine.Approved
AnisodamineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Anisodamine.Investigational
AntipyrineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Antipyrine.Approved
ApremilastThe therapeutic efficacy of Travoprost can be decreased when used in combination with Apremilast.Approved, Investigational
AtenololTravoprost may increase the hypotensive activities of Atenolol.Approved
AzapropazoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Azelastine.Approved
BalsalazideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Balsalazide.Approved, Investigational
BenazeprilTravoprost may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideTravoprost may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Travoprost.Withdrawn
BenoxaprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Benoxaprofen.Withdrawn
BepridilTravoprost may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Travoprost.Approved
BethanidineBethanidine may increase the hypotensive activities of Travoprost.Approved
Betulinic AcidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Betulinic Acid.Investigational
BimatoprostTravoprost may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololTravoprost may increase the hypotensive activities of Bisoprolol.Approved
BosentanTravoprost may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumTravoprost may increase the hypotensive activities of Bretylium.Approved
BrimonidineTravoprost may increase the hypotensive activities of Brimonidine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Travoprost.Approved
BromfenacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Bucillamine.Investigational
BupranololTravoprost may increase the hypotensive activities of Bupranolol.Approved
CandesartanTravoprost may increase the hypotensive activities of Candesartan.Approved
CandoxatrilTravoprost may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilTravoprost may increase the hypotensive activities of Captopril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Travoprost.Withdrawn
CarprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololTravoprost may increase the hypotensive activities of Carteolol.Approved
CarvedilolTravoprost may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololTravoprost may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideTravoprost may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorthalidoneTravoprost may increase the hypotensive activities of Chlorthalidone.Approved
CilazaprilTravoprost may increase the hypotensive activities of Cilazapril.Approved
ClonidineTravoprost may increase the hypotensive activities of Clonidine.Approved
ClonixinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Clonixin.Approved
CryptenamineTravoprost may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe therapeutic efficacy of Travoprost can be decreased when used in combination with Curcumin.Investigational
CyclothiazideTravoprost may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneThe therapeutic efficacy of Travoprost can be decreased when used in combination with D-Limonene.Investigational
DebrisoquinTravoprost may increase the hypotensive activities of Debrisoquin.Approved
DeserpidineTravoprost may increase the hypotensive activities of Deserpidine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Travoprost.Approved
DiclofenacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiflunisalThe therapeutic efficacy of Travoprost can be decreased when used in combination with Diflunisal.Approved
DihydralazineTravoprost may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemTravoprost may increase the hypotensive activities of Diltiazem.Approved
DorzolamideTravoprost may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinTravoprost may increase the hypotensive activities of Doxazosin.Approved
DroxicamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Droxicam.Approved
DuvelisibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Duvelisib.Investigational
E6201The therapeutic efficacy of Travoprost can be decreased when used in combination with E6201.Investigational
EbselenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ebselen.Investigational
EfonidipineTravoprost may increase the hypotensive activities of Efonidipine.Approved
EnalaprilTravoprost may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatTravoprost may increase the hypotensive activities of Enalaprilat.Approved
EpirizoleThe therapeutic efficacy of Travoprost can be decreased when used in combination with Epirizole.Approved
EpoprostenolTravoprost may increase the hypotensive activities of Epoprostenol.Approved
EprosartanTravoprost may increase the hypotensive activities of Eprosartan.Approved
EtanerceptThe therapeutic efficacy of Travoprost can be decreased when used in combination with Etanercept.Approved, Investigational
EtodolacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Travoprost can be decreased when used in combination with Etofenamate.Approved
EtoricoxibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Etoricoxib.Approved, Investigational
Evening primrose oilThe therapeutic efficacy of Travoprost can be decreased when used in combination with Evening primrose oil.Approved
exisulindThe therapeutic efficacy of Travoprost can be decreased when used in combination with exisulind.Investigational
FelodipineTravoprost may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Fenbufen.Approved
FenoldopamTravoprost may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Fenoprofen.Approved
FloctafenineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FlunixinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Flunixin.Vet Approved
FlurbiprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FosinoprilTravoprost may increase the hypotensive activities of Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Travoprost.Approved, Vet Approved
GuanabenzTravoprost may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Travoprost.Approved
GuanethidineTravoprost may increase the hypotensive activities of Guanethidine.Approved
GuanfacineTravoprost may increase the hypotensive activities of Guanfacine.Approved, Investigational
HexamethoniumTravoprost may increase the hypotensive activities of Hexamethonium.Experimental
HigenamineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Higenamine.Investigational
HMPL-004The therapeutic efficacy of Travoprost can be decreased when used in combination with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Travoprost.Approved
HydralazineTravoprost may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideTravoprost may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideTravoprost may increase the hypotensive activities of Hydroflumethiazide.Approved
IbuprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Travoprost can be decreased when used in combination with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Travoprost.Approved, Investigational
ImidaprilTravoprost may increase the hypotensive activities of Imidapril.Investigational
IndapamideTravoprost may increase the hypotensive activities of Indapamide.Approved
IndenololTravoprost may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminTravoprost may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Travoprost.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Travoprost.Withdrawn
IrbesartanTravoprost may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Travoprost.Approved
IsoxicamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Travoprost.Approved
KebuzoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Kebuzone.Experimental
KetanserinTravoprost may increase the hypotensive activities of Ketanserin.Investigational
KetoprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ketorolac.Approved
LabetalolTravoprost may increase the hypotensive activities of Labetalol.Approved
LacidipineTravoprost may increase the hypotensive activities of Lacidipine.Approved
LatanoprostTravoprost may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineTravoprost may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LisinoprilTravoprost may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Lisofylline.Investigational
LofexidineTravoprost may increase the hypotensive activities of Lofexidine.Approved, Investigational
LornoxicamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Lornoxicam.Approved
LosartanTravoprost may increase the hypotensive activities of Losartan.Approved
LoxoprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Loxoprofen.Approved
LumiracoxibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanTravoprost may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Travoprost can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineTravoprost may increase the hypotensive activities of Manidipine.Approved
MasoprocolThe therapeutic efficacy of Travoprost can be decreased when used in combination with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Travoprost.Withdrawn
MecamylamineTravoprost may increase the hypotensive activities of Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mefenamic acid.Approved
MeloxicamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Travoprost can be decreased when used in combination with Metamizole.Withdrawn
MethyldopaTravoprost may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Travoprost.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Travoprost.Approved, Investigational
MetipranololTravoprost may increase the hypotensive activities of Metipranolol.Approved
MetolazoneTravoprost may increase the hypotensive activities of Metolazone.Approved
MetoprololMetoprolol may increase the hypotensive activities of Travoprost.Approved, Investigational
MetyrosineTravoprost may increase the hypotensive activities of Metyrosine.Approved
MibefradilTravoprost may increase the hypotensive activities of Mibefradil.Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Travoprost.Approved
MinoxidilTravoprost may increase the hypotensive activities of Minoxidil.Approved
MizoribineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Travoprost.Approved
MoexiprilTravoprost may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Travoprost.Approved
MoxonidineTravoprost may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mycophenolic acid.Approved
NabumetoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nabumetone.Approved
NadololTravoprost may increase the hypotensive activities of Nadolol.Approved
NafamostatThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nafamostat.Investigational
NaftifineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Naftifine.Approved
NaftopidilTravoprost may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Naproxen.Approved, Vet Approved
NCX 4016The therapeutic efficacy of Travoprost can be decreased when used in combination with NCX 4016.Investigational
NebivololTravoprost may increase the hypotensive activities of Nebivolol.Approved, Investigational
NepafenacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nepafenac.Approved
NialamideNialamide may increase the hypotensive activities of Travoprost.Withdrawn
NicardipineTravoprost may increase the hypotensive activities of Nicardipine.Approved
NicorandilTravoprost may increase the hypotensive activities of Nicorandil.Approved
Niflumic AcidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineTravoprost may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineTravoprost may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NimodipineTravoprost may increase the hypotensive activities of Nimodipine.Approved
NisoldipineTravoprost may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineTravoprost may increase the hypotensive activities of Nitrendipine.Approved
NitroaspirinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nitroaspirin.Investigational
NitroprussideTravoprost may increase the hypotensive activities of Nitroprusside.Approved
ObinutuzumabTravoprost may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Travoprost.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Travoprost.Approved, Investigational
OlopatadineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Olsalazine.Approved
OmapatrilatTravoprost may increase the hypotensive activities of Omapatrilat.Investigational
OrgoteinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Orgotein.Vet Approved
OxaprozinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Oxaprozin.Approved
OxprenololTravoprost may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Oxyphenbutazone.Withdrawn
ParecoxibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Travoprost.Approved
PenbutololTravoprost may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentoliniumTravoprost may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Travoprost.Approved, Investigational
PerindoprilTravoprost may increase the hypotensive activities of Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Travoprost.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Travoprost.Withdrawn
PhenoxybenzamineTravoprost may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Travoprost.Withdrawn
PhentolamineTravoprost may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Travoprost can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilTravoprost may increase the hypotensive activities of Pinacidil.Withdrawn
PindololTravoprost may increase the hypotensive activities of Pindolol.Approved
PirfenidoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Travoprost.Approved
PiroxicamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Travoprost.Withdrawn
PolythiazideTravoprost may increase the hypotensive activities of Polythiazide.Approved
PrazosinTravoprost may increase the hypotensive activities of Prazosin.Approved
PropacetamolThe therapeutic efficacy of Travoprost can be decreased when used in combination with Propacetamol.Approved
PropranololTravoprost may increase the hypotensive activities of Propranolol.Approved, Investigational
PTC299The therapeutic efficacy of Travoprost can be decreased when used in combination with PTC299.Investigational
QuinaprilTravoprost may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Travoprost.Approved
RamiprilRamipril may increase the hypotensive activities of Travoprost.Approved
RasagilineRasagiline may increase the hypotensive activities of Travoprost.Approved
RemikirenRemikiren may increase the hypotensive activities of Travoprost.Approved
RescinnamineTravoprost may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Travoprost.Approved
ResveratrolThe therapeutic efficacy of Travoprost can be decreased when used in combination with Resveratrol.Experimental, Investigational
RilmenidineTravoprost may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatTravoprost may increase the hypotensive activities of Riociguat.Approved
RituximabTravoprost may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
SafrazineSafrazine may increase the hypotensive activities of Travoprost.Withdrawn
SalicylamideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalsalateThe therapeutic efficacy of Travoprost can be decreased when used in combination with Salsalate.Approved
SaprisartanTravoprost may increase the hypotensive activities of Saprisartan.Experimental
SelegilineSelegiline may increase the hypotensive activities of Travoprost.Approved, Investigational, Vet Approved
SelexipagTravoprost may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe therapeutic efficacy of Travoprost can be decreased when used in combination with Seratrodast.Approved, Investigational
SildenafilSildenafil may increase the antihypertensive activities of Travoprost.Approved, Investigational
SitaxentanTravoprost may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilTravoprost may increase the hypotensive activities of Spirapril.Approved
SRT501The therapeutic efficacy of Travoprost can be decreased when used in combination with SRT501.Investigational
SulfasalazineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Sulindac.Approved
SuprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Suprofen.Approved, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Travoprost.Approved, Investigational
TelmisartanTravoprost may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilTravoprost may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tepoxalin.Vet Approved
TeriflunomideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Teriflunomide.Approved
TerlipressinTravoprost may increase the hypotensive activities of Terlipressin.Approved, Investigational
Tiaprofenic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneTravoprost may increase the hypotensive activities of Tibolone.Approved
TicrynafenTravoprost may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTravoprost may increase the hypotensive activities of Timolol.Approved
TinoridineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tinoridine.Investigational
TolazolineTravoprost may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
Tolfenamic AcidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Travoprost.Approved
TorasemideTorasemide may increase the hypotensive activities of Travoprost.Approved
TrandolaprilTravoprost may increase the hypotensive activities of Trandolapril.Approved
TranilastThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Travoprost.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Travoprost.Approved
TreprostinilTravoprost may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideTravoprost may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTravoprost may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTravoprost may increase the hypotensive activities of Trimethaphan.Approved
Trisalicylate-cholineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Travoprost.Approved, Investigational
UnoprostoneTravoprost may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Travoprost.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Travoprost.Approved
VinpocetineTravoprost may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineTravoprost may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Travoprost.Approved, Vet Approved
ZaltoprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Travoprost can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe therapeutic efficacy of Travoprost can be decreased when used in combination with Zomepirac.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4. doi: 10.1016/j.ophtha.2007.07.002. [PubMed:18452763 ]
  2. Costagliola C, dell'Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F: Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother. 2009 Dec;10(17):2859-70. doi: 10.1517/14656560903300129. [PubMed:19929706 ]
  3. Ferrari G, Scagliotti GV: Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients. Eur J Cancer. 1996 Dec;32A(13):2368-9. [PubMed:9038626 ]
  4. Toris CB, Gabelt BT, Kaufman PL: Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008 Nov;53 Suppl1:S107-20. doi: 10.1016/j.survophthal.2008.08.010. [PubMed:19038618 ]
  5. Arranz-Marquez E, Teus MA: Prostanoids for the management of glaucoma. Expert Opin Drug Saf. 2008 Nov;7(6):801-8. doi: 10.1517/14740330802465474 . [PubMed:18983226 ]
External Links
ATC CodesS01EE04
AHFS Codes
  • 52:92.00
PDB EntriesNot Available
FDA labelDownload (36.8 KB)
MSDSDownload (72.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9857
Blood Brain Barrier+0.887
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.5907
P-glycoprotein inhibitor INon-inhibitor0.8237
P-glycoprotein inhibitor IINon-inhibitor0.6435
Renal organic cation transporterNon-inhibitor0.8856
CYP450 2C9 substrateNon-substrate0.8327
CYP450 2D6 substrateNon-substrate0.8383
CYP450 3A4 substrateSubstrate0.652
CYP450 1A2 substrateNon-inhibitor0.728
CYP450 2C9 inhibitorNon-inhibitor0.7607
CYP450 2D6 inhibitorNon-inhibitor0.9125
CYP450 2C19 inhibitorNon-inhibitor0.6844
CYP450 3A4 inhibitorNon-inhibitor0.8546
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7657
Ames testNon AMES toxic0.7427
CarcinogenicityNon-carcinogens0.9088
BiodegradationNot ready biodegradable0.9726
Rat acute toxicity3.5280 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9744
hERG inhibition (predictor II)Non-inhibitor0.6722
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alcon inc
Packagers
Dosage forms
FormRouteStrength
SolutionOphthalmic
SolutionOphthalmic0.003 %
Solution / dropsOphthalmic30 μg/ml
Solution / dropsOphthalmic40 μg/ml
SolutionOphthalmic.04 mg/mL
SolutionOphthalmic0.004 %
Solution / dropsOphthalmic.04 mg/mL
Prices
Unit descriptionCostUnit
Travatan 0.004% Solution 5ml Bottle190.82USD bottle
Travatan Z 0.004% Solution 5ml Bottle190.82USD bottle
Travatan 0.004% Solution 2.5ml Bottle95.41USD bottle
Travatan Z 0.004% Solution 2.5ml Bottle95.41USD bottle
Travatan 0.004% eye drop45.87USD ml
Travatan z 0.004% eye drop36.7USD ml
Travatan 0.004 % Solution12.18USD ml
Travatan Z 0.004 % Solution12.18USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2129287 No2002-05-142014-08-02Canada
CA2181172 No2003-04-292015-12-19Canada
US5631287 No1994-12-222014-12-22Us
US6503497 No1995-05-062012-05-06Us
US8178582 No2009-10-102029-10-10Us
US8268299 No2009-10-132029-10-13Us
US8323630 No2007-09-202027-09-20Us
US8388941 No2007-09-202027-09-20Us
US8722735 No2009-10-102029-10-10Us
US8754123 No2009-05-192029-05-19Us
US9144561 No2009-03-132029-03-13Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
water solubility>16 mg/ml at 25.0°CNot Available
logP4.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00759 mg/mLALOGPS
logP4.02ALOGPS
logP3.84ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)13.95ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area96.22 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity127.86 m3·mol-1ChemAxon
Polarizability51.61 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassEicosanoids
Direct ParentProstaglandins and related compounds
Alternative Parents
Substituents
  • Prostaglandin skeleton
  • Phenol ether
  • Fatty acid ester
  • Alkyl aryl ether
  • Benzenoid
  • Cyclopentanol
  • Monocyclic benzene moiety
  • Cyclic alcohol
  • Secondary alcohol
  • Carboxylic acid ester
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Prostaglandin f receptor activity
Specific Function:
Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis in the corpus luteum (By similarity). Isoforms 2 to 7 do not bind PGF2-alpha but are proposed to modulate signaling by participating in variant receptor complexes; heterodimers between isoform 1 and ...
Gene Name:
PTGFR
Uniprot ID:
P43088
Molecular Weight:
40054.1 Da
References
  1. Ota T, Aihara M, Narumiya S, Araie M: The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4159-63. [PubMed:16249494 ]
  2. Thieme H, Schimmat C, Munzer G, Boxberger M, Fromm M, Pfeiffer N, Rosenthal R: Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci. 2006 Mar;47(3):938-45. [PubMed:16505027 ]
  3. Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4. doi: 10.1016/j.ophtha.2007.07.002. [PubMed:18452763 ]
  4. Neacsu AM: [Receptors involved in the mechanism of action of topical prostaglandines]. Oftalmologia. 2009;53(2):3-7. [PubMed:19697832 ]
  5. Costagliola C, dell'Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F: Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother. 2009 Dec;10(17):2859-70. doi: 10.1517/14656560903300129. [PubMed:19929706 ]
  6. Ferrari G, Scagliotti GV: Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients. Eur J Cancer. 1996 Dec;32A(13):2368-9. [PubMed:9038626 ]
  7. Toris CB, Gabelt BT, Kaufman PL: Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008 Nov;53 Suppl1:S107-20. doi: 10.1016/j.survophthal.2008.08.010. [PubMed:19038618 ]
  8. Arranz-Marquez E, Teus MA: Prostanoids for the management of glaucoma. Expert Opin Drug Saf. 2008 Nov;7(6):801-8. doi: 10.1517/14740330802465474 . [PubMed:18983226 ]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:44